Novo Nordisk A/S: Rybelsus (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults…
Ozempic (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025
Ozempic® improved maximum walking distance by 13% vs placebo in adults with…
Novo Nordisk’s sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024
Bagsværd, 5 February 2025 - Financial report for the period 1 January…
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results…
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions…
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions…
Novo Nordisk A/S – share repurchase programme
Bagsværd, Denmark, 18 November 2024 – On 11 November 2024, Novo Nordisk…
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 8 November 2024 – This company announcement discloses the data…
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 7 November 2024 — This company announcement discloses the data…